<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>NSAIDs (including aspirin): Pharmacology and mechanism of action</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">NSAIDs (including aspirin): Pharmacology and mechanism of action</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">NSAIDs (including aspirin): Pharmacology and mechanism of action</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel H Solomon, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>More than 20 different nonsteroidal antiinflammatory drugs (NSAIDs) are available commercially, and these agents are used worldwide for their analgesic, antipyretic, and antiinflammatory effects in patients with multiple medical conditions. NSAIDs, including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, do not generally change the course of the disease process in those conditions, where they are used for symptomatic relief.</p><p>The pharmacology and mechanisms of action of the NSAIDs, including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, will be reviewed here. A more detailed discussion of mechanism of aspirin relevant to primary prevention of cardiovascular disease and cancer can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer", section on 'Mechanisms of action'</a>.)</p><p>The uses of NSAIDs in specific disorders are discussed elsewhere (see appropriate topic reviews). The therapeutic variability and approach to the clinical use of NSAIDs, including their use in combination with other medications and in patients with comorbid conditions; the adverse effects of NSAIDs; and an overview of cyclooxygenase 2 (COX-2) selective NSAIDs are described in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs"</a>.)</p><p></p><p class="headingAnchor" id="H8064364"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span>There are more than 20 different nonsteroidal antiinflammatory drugs (NSAIDs), from six major classes determined by their chemical structures, available for use worldwide. These drugs differ in their dose, drug interactions, and some side effects  (<a class="graphic graphic_table graphicRef70067" href="/z/d/graphic/70067.html" rel="external">table 1</a>). Most NSAIDs are absorbed completely, have negligible first-pass hepatic metabolism, are tightly bound to serum proteins, and have small volumes of distribution.</p><p>NSAIDs undergo hepatic transformations variously by cytochrome P4502C8 (CYP2C8), 2C9, 2C19 and/or glucuronidation. Half-lives of the NSAIDs vary but in general can be divided into "short-acting" (less than six hours, including <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, <a class="drug drug_general" data-topicid="8590" href="/z/d/drug information/8590.html" rel="external">ketoprofen</a> and <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a>) and "long-acting" (more than six hours, including <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>, <a class="drug drug_general" data-topicid="10295" href="/z/d/drug information/10295.html" rel="external">meloxicam</a>, <a class="drug drug_general" data-topicid="9671" href="/z/d/drug information/9671.html" rel="external">nabumetone</a>, and <a class="drug drug_general" data-topicid="9781" href="/z/d/drug information/9781.html" rel="external">piroxicam</a>). Patients with hypoalbuminemia (due, for example, to cirrhosis or active rheumatoid arthritis) may have a higher free serum concentration of the drug.</p><p>Assessment of toxicity and therapeutic response to a given NSAID must take into account the time needed to reach the steady state plasma concentration (roughly equal to three to five half-lives of the drug). Like other drugs, NSAIDs with a longer half-life tend to have greater enterohepatic circulation of active metabolites.</p><p>Potential pharmacologic mechanisms to explain variability in the response to different NSAIDs are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults", section on 'Pharmacologic properties and clinical effects'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">MECHANISMS OF ANALGESIA AND ANTIINFLAMMATORY EFFECTS</span></p><p class="headingAnchor" id="H5"><span class="h2">Cyclooxygenase inhibition</span><span class="headingEndMark"> — </span>The primary effect of nonsteroidal antiinflammatory drugs (NSAIDs) is to inhibit cyclooxygenase (COX; prostaglandin synthase), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes  (<a class="graphic graphic_figure graphicRef66146" href="/z/d/graphic/66146.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. The extent of enzyme inhibition varies among the different NSAIDS  (<a class="graphic graphic_figure graphicRef82145" href="/z/d/graphic/82145.html" rel="external">figure 2</a>), although there are no studies relating the degree of COX inhibition with antiinflammatory efficacy in individual patients [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Cyclooxygenase enzymes</span><span class="headingEndMark"> — </span>Two related isoforms of the COX enzyme have been described [<a href="#rid4">4,5</a>]: COX-1 (prostaglandin-H-synthase 2 [PGHS-1]) and COX-2 (PGHS-2). The COX-1 and COX-2 isoforms possess 60 percent homology in those amino acid sequences apparently conserved for catalysis of arachidonic acid [<a href="#rid6">6-10</a>]. A splice variant derived from the COX-1 gene has been described, but the relevance of this isoform is still unclear.</p><p>The degree to which a particular NSAID inhibits an isoform of cyclooxygenase may affect both its activity and toxicity; there are important differences in the regulation and expression of these enzymes in various tissues:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclooxygenase 1</strong> – COX-1 is expressed in most tissues but variably. It is described as a "housekeeping" enzyme, regulating normal cellular processes (such as gastric cytoprotection, vascular homeostasis, platelet aggregation, and kidney function), and is stimulated by hormones or growth factors.</p><p></p><p class="bulletIndent1">An enzyme originally termed COX-3 is a splice variant of COX-1 denoted COX-1b; the role of this enzyme is unclear and remains controversial [<a href="#rid11">11,12</a>]. The messenger ribonucleic acid (mRNA) for COX-1b appears to be expressed at a high level in the central nervous system, with transcripts accounting for 5 percent of COX mRNA in some studies; it has also been found in the heart [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclooxygenase 2</strong> – COX-2 is a highly regulated enzyme that is constitutively expressed in the brain, kidney, and bone, and probably in the female reproductive system, but is undetectable in most other tissues [<a href="#rid15">15</a>]. Its expression is increased during states of inflammation, or experimentally in response to mitogenic stimuli. As an example, growth factors, phorbol esters, and interleukin 1 (IL-1) stimulate the expression of COX-2 in fibroblasts, while endotoxin serves the same function in monocytes/macrophages [<a href="#rid5">5,16</a>].</p><p></p><p class="bulletIndent1">Another distinguishing characteristic of COX-2 is that its expression is inhibited by glucocorticoids [<a href="#rid17">17</a>]. This observation may contribute to the significant antiinflammatory effects of the glucocorticoids. The efficacy and safety of selective COX-2 inhibitors are discussed in further detail separately. (See  <a class="medical medical_review" href="/z/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs"</a>.)</p><p></p><p>COX-2 has an important role in the inflammatory process, although the effect of selective COX-2 inhibition on inflammation is not completely understood:</p><p class="bulletIndent1"><span class="glyph">●</span>COX-2 knockout mice are less susceptible to inflammation in some models than intact mice, but responses differ depending upon the model of inflammation used [<a href="#rid18">18-20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conversely, COX-2 may have antiinflammatory properties. In an animal model of inflammation and carrageenin-induced pleurisy, one study showed that maximal COX-2 expression coincided with inflammatory resolution and was associated with minimal prostaglandin E2 synthesis [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human T lymphocytes express the COX-2 isoenzyme where it may serve a role in both the early and late events of T-cell activation, such as the production of IL-2, tumor necrosis factor (TNF)-alpha, and interferon-gamma [<a href="#rid22">22</a>].</p><p></p><p>Some older NSAIDs are also relatively selective for the COX-2 receptor at low doses. <a class="drug drug_general" data-topicid="9671" href="/z/d/drug information/9671.html" rel="external">Nabumetone</a>, for example, appears to be a more effective inhibitor in some experimental systems of COX-2 than COX-1 [<a href="#rid23">23</a>]. <a class="drug drug_general" data-topicid="8427" href="/z/d/drug information/8427.html" rel="external">Etodolac</a> also inhibits the COX-2 isoform more than COX-1 (10 to 1 ratio) [<a href="#rid24">24,25</a>]. Further discussion relating to COX-2 inhibitors is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Salicylate-specific effects</span><span class="headingEndMark"> — </span>Salicylates include <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, also known as acetylsalicylic acid. While salicylates generally have the same mechanisms of action as other NSAIDs, there are some differences in their effect on COX inhibition.</p><p>Salicylates are very potent inhibitors of both COX-1 and COX-2 in a human whole-cell system, and COX-2 is more sensitive to the effects of the drug than COX-1 [<a href="#rid26">26</a>]. However, salicylates barely inhibit the COX enzyme in pure cell-free enzyme systems, and their effects are not measurable in cell membrane systems. Clinical studies have shown that nonacetylated salicylates (such as <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a>) may be as effective as other NSAIDs with respect to their antiinflammatory effects in patients with rheumatoid arthritis, despite evidence suggesting that they are not as good prostaglandin synthesis inhibitors in vitro [<a href="#rid27">27</a>].</p><p>The effects of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> on COX-2 activity are very different from the effects on COX-1 [<a href="#rid28">28</a>]. Acetylated COX-1 and COX-2 cannot form the intermediate products of prostaglandin synthesis. However, acetylated COX-2 retains the capacity to alter arachidonic acid to form 15(R)-hydroxyeicosatetraenoic acid (15R-HETE), while acetylated COX-1 does not. 15R-HETE has unknown biochemical effects, but it may be important as a modulator of proliferation since it is a product of an inducible enzyme during states of inflammation [<a href="#rid28">28</a>]. This effect on proliferation may have several interesting ramifications, including the use of aspirin for the prevention of colon cancer. (See <a class="local">'Apoptosis'</a> below and  <a class="medical medical_review" href="/z/d/html/2600.html" rel="external">"NSAIDs (including aspirin): Role in prevention of colorectal cancer"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Non-prostaglandin-mediated effects</span><span class="headingEndMark"> — </span>Several non-prostaglandin-mediated mechanisms of action have been postulated to explain the antiinflammatory actions of the nonacetylated salicylates, which may apply to a varying degree to nonsalicylate NSAIDs [<a href="#rid2">2,3</a>]. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> (the only acetylated NSAID) is not thought to have antiinflammatory effects other than those related to inhibition of prostaglandin synthesis. The role of these non-prostaglandin-mediated processes in clinical inflammation remains unclear. Despite the fact that nonacetylated salicylates have shown equal antiinflammatory efficacy when compared with acetylsalicylic acid in patients with rheumatoid arthritis [<a href="#rid29">29</a>], it may be that these drugs also inhibit COX when used at the doses required to achieve an antiinflammatory response [<a href="#rid2">2,3,30</a>].</p><p>Examples of potential non-prostaglandin-mediated mechanisms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Some of these effects appear to be related to the physicochemical property of NSAIDs that enables them to insert into biological membranes and disrupt important interactions necessary for cell function (eg, transmembrane anion transport, oxidative phosphorylation, and uptake of arachidonate) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophil function is inhibited by nonacetylated salicylates and other nonsalicylate NSAIDs in vitro. As an example, NSAIDs interfere with the neutrophil-endothelial cell adherence that is critical for the ability to respond to inflammation. NSAIDs decrease the expression of L-selectin, which removes a crucial step in the migration of granulocytes to sites of inflammation [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NSAIDS have also been demonstrated in vitro to inhibit nuclear factor (NF)-kappaB-dependent transcription, leading to inhibition of inducible nitric oxide synthetase (iNOS) [<a href="#rid33">33</a>]. NOS, once induced by cytokines and other proinflammatory mediators, produces NO in large amounts, thereby leading to increased inflammation (including vasocongestion, cytotoxicity, and vascular permeability) [<a href="#rid34">34</a>]. Therapeutic levels of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> inhibit expression of iNOS and the subsequent production of nitrite in vitro [<a href="#rid33">33</a>]. Sodium salicylate and <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> have no such effects at pharmacologic doses, although sodium salicylate also inhibits nitrite production at suprapharmacologic dosages [<a href="#rid33">33</a>]. The inhibition of NF-kappaB by salicylates may be responsible for the capacity of salicyl salicylate (<a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a>) to reduce levels of HbA<sub>1c</sub> and to improve other markers of glycemic control in patients with type 2 diabetes; such studies were based, in part, on the observation that NF-kappaB is activated by obesity and promotes insulin resistance and risk for type 2 diabetes and cardiovascular disease [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Apoptosis</span><span class="headingEndMark"> — </span>A novel effect of NSAIDs has been described involving prostaglandin inhibition. Prostaglandins inhibit apoptosis (programmed cell death) in vivo. NSAIDs establish a more normal cell cycle in the inflammatory state by inhibiting prostaglandins and therefore allowing for more apoptosis [<a href="#rid36">36</a>].</p><p>An important extension of these observations may be the association between the use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, and perhaps other NSAIDs, and a reduced risk of colorectal cancer (see  <a class="medical medical_review" href="/z/d/html/2600.html" rel="external">"NSAIDs (including aspirin): Role in prevention of colorectal cancer"</a>). The mechanism of this protective effect cannot be entirely attributed to inhibition of prostaglandin synthesis. The two prerequisites for the development of cancer are proliferation and the inhibition of apoptosis. One study found that <a class="drug drug_general" data-topicid="9967" href="/z/d/drug information/9967.html" rel="external">sulindac</a> decreased the size of adenomatous polyps in patients with familial adenomatous polyposis by increasing apoptosis rather than altering proliferation [<a href="#rid37">37</a>]. <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">Celecoxib</a> has also been shown to reduce the development of adenomas in patients with familial adenomatous polyposis and in patients with sporadic adenomatous polyps [<a href="#rid38">38-40</a>]. However, its use for this indication is not widely embraced because of concerns regarding the risk-benefit ratio for this agent at the doses used in these trials.</p><p class="headingAnchor" id="H10"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/519.html" rel="external">"Patient education: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3847375"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – All nonsteroidal antiinflammatory drugs (NSAIDs) are absorbed completely, have negligible first-pass hepatic metabolism, are tightly bound to albumin, and have small volumes of distribution. Half-lives of the NSAIDs vary but, in general, can be divided into "short-acting" (less than six hours) and "long-acting" (more than six hours) drugs. Patients with hypoalbuminemia (due, for example, to cirrhosis or active rheumatoid arthritis) may have a higher free serum concentration of the drug. (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of analgesia and antiinflammatory effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cyclooxygenase inhibition</strong> – The primary effect of NSAIDs is to inhibit cyclooxygenase (COX; prostaglandin synthase), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. The extent of enzyme inhibition varies among the different NSAIDS, although there are no studies relating the degree of COX inhibition with antiinflammatory efficacy in individual patients. Differences in the effectiveness with which a particular NSAID inhibits an isoform of COX may affect both its activity and toxicity. (See <a class="local">'Cyclooxygenase inhibition'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cyclooxygenase enzymes</strong> – Two related isoforms of the COX enzyme have been well characterized: COX-1 (prostaglandin-H-synthase 2 [PGHS-1]) and COX-2 (PGHS-2). COX-1 is expressed in most tissues but variably. It is described as a "housekeeping" enzyme, regulating normal cellular processes (such as gastric cytoprotection, vascular homeostasis, platelet aggregation, and kidney function), and is stimulated by hormones or growth factors. COX-2 is usually undetectable in most tissues; its expression is increased during states of inflammation, or experimentally in response to mitogenic stimuli. COX-2 is constitutively expressed in the brain, kidney, and bone, and probably in the female reproductive system; the expression of COX-2 is inhibited by glucocorticoids. Differences in the effectiveness with which a particular NSAID inhibits an isoform of COX may affect both its activity and toxicity. (See <a class="local">'Cyclooxygenase enzymes'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Salicylate-specific effects</strong> – While salicylates generally have the same mechanisms of action as other NSAIDs, there are some differences in their effect on COX inhibition. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and other salicylates barely inhibit the COX enzyme in pure cell-free enzyme systems, and, in cell membrane systems, their effects are not measurable. However, they are very potent inhibitors of both COX-1 and COX-2 in a human whole-cell system, and COX-2 is more sensitive to the effects of the drug than COX-1. Clinical studies have shown that nonacetylated salicylates (such as <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a>) may be as effective as other NSAIDs for patients with rheumatoid arthritis, despite evidence that they are not good prostaglandin synthesis inhibitors in vitro. (See <a class="local">'Salicylate-specific effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-prostaglandin-mediated effects</strong> – Several non-prostaglandin-mediated mechanisms of action have been postulated to explain the actions of the nonacetylated salicylates; these observations may also apply to the nonsalicylate NSAIDs to varying degrees. Potential mechanisms include disruption of interactions necessary for cell function through actions in cell membranes and inhibition of neutrophil function. NSAIDS have also been demonstrated in vitro to inhibit nuclear factor (NF)-kappaB-dependent transcription, leading to inhibition of inducible nitric oxide synthetase (iNOS). (See <a class="local">'Non-prostaglandin-mediated effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Apoptosis</strong> – Prostaglandins inhibit apoptosis (programmed cell death) in vivo. NSAIDs establish a more normal cell cycle in the inflammatory state by inhibiting prostaglandins and therefore allowing for more apoptosis. An important extension of these observations may be the association between the use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, and perhaps other NSAIDs, and a reduced risk of colorectal cancer. (See <a class="local">'Apoptosis'</a> above and  <a class="medical medical_review" href="/z/d/html/2600.html" rel="external">"NSAIDs (including aspirin): Role in prevention of colorectal cancer"</a>.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232.</a></li><li><a class="nounderline abstract_t">Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med 1991; 324:1716.</a></li><li><a class="nounderline abstract_t">Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989; 32:1.</a></li><li><a class="nounderline abstract_t">Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610.</a></li><li><a class="nounderline abstract_t">DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993; 95:40S.</a></li><li><a class="nounderline abstract_t">DeWitt DL, el-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990; 265:5192.</a></li><li><a class="nounderline abstract_t">Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992; 267:12387.</a></li><li><a class="nounderline abstract_t">Shimokawa T, Smith WL. Essential histidines of prostaglandin endoperoxide synthase. His-309 is involved in heme binding. J Biol Chem 1991; 266:6168.</a></li><li><a class="nounderline abstract_t">Shimokawa T, Kulmacz RJ, DeWitt DL, Smith WL. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem 1990; 265:20073.</a></li><li><a class="nounderline abstract_t">Toh H. Prostaglandin endoperoxide synthase contains an EGF-like domain. FEBS Lett 1989; 258:317.</a></li><li><a class="nounderline abstract_t">Hersh EV, Lally ET, Moore PA. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? Curr Med Res Opin 2005; 21:1217.</a></li><li><a class="nounderline abstract_t">Reinauer C, Censarek P, Kaber G, et al. Expression and translation of the COX-1b gene in human cells--no evidence of generation of COX-1b protein. Biol Chem 2013; 394:753.</a></li><li><a class="nounderline abstract_t">Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99:13926.</a></li><li><a class="nounderline abstract_t">Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361:981.</a></li><li><a class="nounderline abstract_t">Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063.</a></li><li><a class="nounderline abstract_t">Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267:25934.</a></li><li><a class="nounderline abstract_t">O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 1992; 89:4888.</a></li><li><a class="nounderline abstract_t">Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473.</a></li><li><a class="nounderline abstract_t">Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378:406.</a></li><li><a class="nounderline abstract_t">Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31:986.</a></li><li><a class="nounderline abstract_t">Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698.</a></li><li><a class="nounderline abstract_t">Iñiguez MA, Punzón C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999; 163:111.</a></li><li><a class="nounderline abstract_t">Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med 1996; 156:1623.</a></li><li><a class="nounderline abstract_t">Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271:1705.</a></li><li><a class="nounderline abstract_t">Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281:107.</a></li><li><a class="nounderline abstract_t">Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993; 90:11693.</a></li><li><a class="nounderline abstract_t">Bombardier C, Peloso PM, Goldsmith CH. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group. J Rheumatol 1995; 22:617.</a></li><li><a class="nounderline abstract_t">Marcus AJ. Aspirin as prophylaxis against colorectal cancer. N Engl J Med 1995; 333:656.</a></li><li><a class="nounderline abstract_t">Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? The Multicenter Salsalate/Aspirin Comparison Study Group. J Rheumatol 1989; 16:321.</a></li><li><a class="nounderline abstract_t">Stevenson DD, Hougham AJ, Schrank PJ, et al. Salsalate cross-sensitivity in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 1990; 86:749.</a></li><li><a class="nounderline abstract_t">Díaz-González F, Sánchez-Madrid F. NSAIDs: learning new tricks from old drugs. Eur J Immunol 2015; 45:679.</a></li><li><a class="nounderline abstract_t">Díaz-González F, González-Alvaro I, Campanero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995; 95:1756.</a></li><li><a class="nounderline abstract_t">Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1995; 92:7926.</a></li><li><a class="nounderline abstract_t">Hawkey CJ. Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs? Gastroenterology 1995; 109:614.</a></li><li><a class="nounderline abstract_t">Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152:346.</a></li><li><a class="nounderline abstract_t">Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci U S A 1995; 92:7961.</a></li><li><a class="nounderline abstract_t">Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109:994.</a></li><li><a class="nounderline abstract_t">Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 2010; 105:1437.</a></li><li><a class="nounderline abstract_t">Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885.</a></li><li><a class="nounderline abstract_t">Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873.</a></li></ol></div><div id="topicVersionRevision">Topic 7989 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5284360" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2034249" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nonsteroidal antiinflammatory drugs--differences and similarities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643434" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The mechanisms of action of nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8454631" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8357002" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2108169" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1601897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prostaglandin endoperoxide synthase. The aspirin acetylation region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901057" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Essential histidines of prostaglandin endoperoxide synthase. His-309 is involved in heme binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2122967" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2513231" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prostaglandin endoperoxide synthase contains an EGF-like domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083531" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362192" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Expression and translation of the COX-1b gene in human cells--no evidence of generation of COX-1b protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12242329" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660052" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : COX-3: just another COX or the solitary elusive target of paracetamol?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737710" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cyclooxygenase in biology and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1464605" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1594589" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8521477" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477380" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508345" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prostaglandins and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371510" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Inducible cyclooxygenase may have anti-inflammatory properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10384106" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694659" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : NSAID gastropathy. A new understanding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7996488" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8566109" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8265610" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791151" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637730" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Aspirin as prophylaxis against colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2657048" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? The Multicenter Salsalate/Aspirin Comparison Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229840" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Salsalate cross-sensitivity in aspirin-sensitive patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25523026" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : NSAIDs: learning new tricks from old drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7535797" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7544010" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615213" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231565" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7644521" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657130" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20234350" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The safety and efficacy of celecoxib in children with familial adenomatous polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943401" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Celecoxib for the prevention of colorectal adenomatous polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16943400" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Celecoxib for the prevention of sporadic colorectal adenomas.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
